多柔吡星注射剂治疗带状疱疹后遗神经痛的临床研究

Clinical trial of doxorubicin injection in the treatment of post-herpetic neuralgia

目的观察多柔吡星注射剂治疗带状疱疹后遗神经痛的临床疗效及安全性。方法将104例带状疱疹后遗神经痛患者随机分为对照组52例和试验组52例。对照组予以脉冲射频治疗,每周2次,每次3 min;试验组予以多柔吡星每次10 mg,每2周1次,经椎间孔注射。2组患者均治疗4周。比较2组患者的临床疗效、视觉模拟评分法(VAS)评分、血清中白细胞介素-6(IL-6)和IL-10水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为86.54%(45例/52例)和69.23%(36例/52例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组血清中IL-6分别为(174.83±23.72)和(321.65±45.82)pg·mL^(-1),IL-10分别为(183.46±28.11)和(164.67±21.31)μg·mL^(-1),VAS评分分别为(2.32±0.65)和(3.51±0.84)分,差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有阻滞区皮肤麻木和心慌,对照组未发生药物不良反应。试验组和对照组的总药物不良反应发生率为5.77%和0,差异无统计学意义(P>0.05)。结论多柔吡星注射剂治疗带状疱疹后遗神经痛的临床疗效确切,促进炎性因子平衡,有效改善患者的疼痛症状,且不增加药物不良反应的发生率。

Objective To observe the clinical efficacy and safety of doxorubicin injection in the treatment of post- herpetic neuralgia. Methods One hundred and four patients with post -herpetic neuralgia were randomly divided into control and treatment groups with 52 cases per group. Control group was given pulse radiofrequency therapy with 3 min per time, twice a week. Treatment group was given doxorubicin 10 mg per time, once two weeks, intervertebral foramen injection. Two groups were treated for 4 weeks. The clinical efficacy, visual analogue scale （VAS） scores, the levels of serum interleukin -6 （IL -6） and IL - 10, and adverse drug reactions were compared between two groups. Results After treatment, the total effective rates of treatment and control groups were 86. 54% （45 cases/52 cases） and 69.23% （36 cases/52 cases） with significant difference （ P 〈 0. 05 ） . After treatment, the main indexes in treatment and control groups were compared： IL -6 were （174.83±23.72） and （321.65 ±45.82） pg·m L-1, IL-10 were （183.46 ± 28.11） and （164.67 ± 21.31） pg·m L-1, VAS were （2. 32 ± 0. 65 ） and （3.51 ± 0. 84） score, the differences were statisticallysignificant （ all P 〈 0.05 ）. The adverse drug reactions in treatment group were skin numbness in block area and palpi- tation, and no adverse drug reactions occurred in control group. The incidences of adverse drug reactions in treatment and control groups were 5.77% and 0 without significant difference （ P 〉 0. 05 ）. Conclusion Doxorubicin injection has a definitive clinical efficacy in the treatment of post - herpetic neuralgia, which can significantly balance the inflam- matory factors, improve the pain, without increasing the incidence of adverse drug reactions